Licensing agreement deals decline in rare diseases space, says report
New research has shown that complex collaborations and partnerships are increasing, while licensing agreements are decreasing in the rare disease space.
List view / Grid view
New research has shown that complex collaborations and partnerships are increasing, while licensing agreements are decreasing in the rare disease space.
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.